Pharming Group N.V. (PHAR) Q4 2024 Earnings
PHAR·Reported March 13, 2025·Before market open
Pharming Group N.V. reported Q4 2024 revenue of $96.0M (+6.6% YoY), beat analyst consensus of $60.9M by $35.0M. Diluted EPS came in at $0.05, missed the $0.07 consensus by $0.02.
Revenue
$96.0Mbeat by $35.0M
Consensus: $60.9MDiluted EPS
$0.05missed by $0.02
Consensus: $0.07
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2024 Earnings FAQ
Common questions about Pharming Group N.V.'s Q4 2024 earnings report.
Pharming Group N.V. (PHAR) reported Q4 2024 earnings on March 13, 2025 before market open.
Pharming Group N.V. reported revenue of $96.0M and diluted EPS of $0.05 for Q4 2024.
Revenue beat the consensus estimate of $60.9M by $35.0M. EPS missed the consensus estimate of $0.07 by $0.02.
Compared to the same quarter a year prior, revenue grew 6.6% from $90.0M a year earlier.